Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation AHI ‐ after 6 weeks Number of participants: 30(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Very low |
Adaptive servo ventilation (ASV) vs bilevel ventilation All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Central AHI ‐ after 3 months Number of participants: 60(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of life ‐ after 3 months Number of participants: 61(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) AHI ‐ after 3 months Number of participants: 60(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Central AHI ‐ after 6 weeks Number of participants: 30(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs bilevel ventilation Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation AHI ‐ after 6 weeks Number of participants: 30(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs bilevel ventilation All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Central AHI Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Cardiovascular mortality ‐ up to 80 months Number of participants: 1325(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | RR 1.25 [1.04, 1.49] | NR | Moderate |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Quality of life ‐ after 48 months Number of participants: 1325(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control AHI ‐ after 6 months Number of participants: 30(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control All‐cause mortality ‐ up to 80 months Number of participants: 1355(2 RCTs) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | RR 0.56 [0.06, 4.93] | NR | Low |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care AHI ‐ after up to 3 months Number of participants: 264(4 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care All‐cause mortality ‐ after 24 months Number of participants: 287(2 RCTs) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | RR 1.14 [0.83, 1.56] | NR | Very low |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Time to life‐saving cardiovascular intervention ( Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Central AHI Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Digital adherence interventions vs usual care Adherence (percentage of people adhering to their prescribed medication) · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | no estimate extracted | 16 studies · 8885 participants | Low |
Digital adherence interventions vs usual care Asthma control ‐ change from baseline (various scales; higher scores = better asthma control ‐ standardised for different scales, scale reversed if in opposite direction) · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | no estimate extracted | 15 studies · 1638 participants | Moderate |
Digital adherence interventions vs usual care Asthma exacerbations ‐ Number of people with one or more exacerbations · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | RR 0.53 [0.32, 0.91] | 6 studies · 678 participants | Low |
Digital adherence interventions vs usual care Unscheduled healthcare utilisation ‐ number of hospital or GP/ED visits · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | RR 0.74 [0.51, 1.06] | 4 studies · 446 participants | Low |
Digital adherence interventions vs usual care Lung function ‐ FEV1 % predicted (change from baseline) · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | no estimate extracted | 7 studies · 1052 participants | Moderate |
Digital adherence interventions vs usual care Quality of life ‐ change from baseline (various scales; higher scores indicate better quality of life) · asthma Digital interventions to improve adherence to maintenance medication in asthma (2022) · Cochrane | no estimate extracted | 10 studies · 848 participants | Moderate |
14 days on/off antibiotic regimen vs 14 days on/off placebo regimen Exacerbation frequency · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | RR 0.75 [0.61, 0.93] | NR | Moderate |
28 days on/off antibiotic regimen vs 28 days on/off placebo regimen Serious adverse events · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | OR 1 [0.68, 1.46] | NR | Low |
28 days on/off antibiotic regimen vs 28 days on/off placebo regimen Antibiotic resistance · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | OR 2.2 [1.42, 3.42] | NR | High |
28 days on/off antibiotic regimen vs 28 days on/off placebo regimen Hospitalisation for pulmonary exacerbations · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | OR 0.79 [0.49, 1.29] | NR | High |
28 days on/off antibiotic regimen vs 28 days on/off placebo regimen Health‐related quality of life · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | Moderate |
28 days on/off antibiotic regimen vs 28 days on/off placebo regimen Health‐related quality of life · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | Low |
14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen Exacerbation frequency · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | RR 1.02 [0.84, 1.24] | NR | Moderate |
14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen Exacerbation frequency · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | No studies |